EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Lowered to $33.00 at Robert W. Baird

EyePoint Pharmaceuticals (NASDAQ:EYPT) had its price target decreased by Robert W. Baird from $38.00 to $33.00 in a research note released on Monday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Other research analysts have also issued research reports about the stock. Scotiabank started coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 price target on the stock. StockNews.com raised EyePoint Pharmaceuticals to a “sell” rating in a research report on Saturday, September 21st. Jefferies Financial Group assumed coverage on EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They set a “buy” rating and a $15.00 price target for the company. JPMorgan Chase & Co. cut their price objective on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of EyePoint Pharmaceuticals in a research report on Friday, October 25th. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $28.00.

EyePoint Pharmaceuticals Stock Performance

NASDAQ:EYPT opened at $12.00 on Monday. The company has a market capitalization of $642.22 million, a P/E ratio of -6.00 and a beta of 1.50. The stock’s 50 day moving average price is $9.56 and its 200 day moving average price is $9.94. EyePoint Pharmaceuticals has a 52 week low of $5.86 and a 52 week high of $30.99.

Hedge Funds Weigh In On EyePoint Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Janney Montgomery Scott LLC grew its position in EyePoint Pharmaceuticals by 26.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 18,040 shares of the company’s stock worth $373,000 after purchasing an additional 3,780 shares during the last quarter. Swiss National Bank acquired a new stake in shares of EyePoint Pharmaceuticals during the 1st quarter worth approximately $1,792,000. ProShare Advisors LLC bought a new stake in shares of EyePoint Pharmaceuticals during the first quarter valued at approximately $209,000. Entropy Technologies LP acquired a new position in shares of EyePoint Pharmaceuticals in the first quarter valued at $279,000. Finally, Vanguard Group Inc. boosted its stake in EyePoint Pharmaceuticals by 17.8% during the first quarter. Vanguard Group Inc. now owns 2,396,228 shares of the company’s stock worth $49,530,000 after buying an additional 362,168 shares in the last quarter. Institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.